Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis
Empagliflozin and metformin are widely used for the treatment of type 2 diabetes. These drugs showed marked anti-inflammatory effects in different animal models via enhancing AMPK activity. Yet, the protective anti-inflammatory effects of their combination against ulcerative colitis have not been pr...
Main Authors: | Mahmoud E. Youssef, Eslam E. Abd El-Fattah, Amir M. Abdelhamid, Hanan Eissa, Eman El-Ahwany, Noha A. Amin, Helal F. Hetta, Mohamed H. Mahmoud, Gaber El-Saber Batiha, Naglaa Gobba, Ahmed Gaafar Ahmed Gaafar, Sameh Saber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.719984/full |
Similar Items
-
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
by: Mojca Lunder, et al.
Published: (2018-12-01) -
Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells
by: Markus Pirklbauer, et al.
Published: (2021-05-01) -
Effect of metformin and empagliflozin on adiponectin and leptin levels in rat model of hypo- and hyperthyroidism
by: Desimira Mironova, et al.
Published: (2021-01-01) -
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
by: Hirotatsu Nakaguchi, et al.
Published: (2020-11-01) -
Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)